The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Clinical trial NCT06015282 · COMPLETED

Trial details

NCT number: NCT06015282
Sponsor: Seqirus
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Influenza, Human

Start date: 2023-11-03
Primary completion: 2024-03-05
Enrollment: 7741

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.